<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468010</url>
  </required_header>
  <id_info>
    <org_study_id>B2017-105-01</org_study_id>
    <nct_id>NCT03468010</nct_id>
  </id_info>
  <brief_title>A Trial Comparing Adjuvant Chemotherapy With Observation After Concurrent Chemoradiotherapy of Cervical Cancer (With Pelvic or Para-aortic Node Involvement)</brief_title>
  <official_title>Adjuvant Chemotherapy Versus Observation After Radiation With Concurrent Cisplatin of Cervical Cancer (With Pelvic or Para-aortic Node Involvement) :A Phase 3 Prospective Multi-institutional Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical cancer with pelvic or para-aortic node involvement has a poor prognosis. Despite
      low-quality data, the routine practice to treat these patients is radiation with concurrent
      cisplatin. The aim of this study is to compare systemic chemotherapy with observation after
      radiation with concurrent cisplatin of cervical cancer ( with pelvic or para-aortic node
      involvement) for incidence of adverse events and local recurrence rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Background Cervical Cancer is one of the most common malignant tumors of Chinese
           females. Women with evidence of para-aortic node involvement have a poor prognosis with
           a five-year survival rate of approximately 40 percent. Despite low-quality data, the
           routine practice to treat these patients is radiation with concurrent cisplatin. It is
           not clear whether systemic chemotherapy delivered following RT will obtain survival
           benefit.

        2. Objective The aim of this study is to compare systemic chemotherapy with observation
           after radiation with concurrent cisplatin of cervical cancer ( with pelvic or
           para-aortic node involvement) for incidence of adverse events, 3y-PFS and 5y-OS, .

        3. Patients

      A patient will be enrolled when patient have:

        1. Pathologically diagnosed cervical cancer;

        2. pelvic or para-aortic lymph metastases, at least match one of following

             -  CT or MRI scan shows pelvic or para-aortic node with a minimal axial diameter
                diameter ≥ 7mm in the largest plane

             -  pelvic or para-aortic lymph node shows necrosis or extra capsular spread

             -  PET/CT scan finds positive pelvic or para-aortic node lymph node

             -  biopsy confirms lymph metastase

        3. Stage IB1-IVA diseases (FIGO system ver. 2014) without treatment before;

        4. Karnofsky Performance Scores ≥ 70;

      4.Method

        1. Randomization is performed to divide the patients into the control group (Group A) and
           the experimental group (Group B). In Group A, observation is given after radiation with
           concurrent cisplatin. But in Group B, three cycles of adjuvant chemotherapy ( Paclitaxel
           plus Cisplatin) are administered after radiation with concurrent cisplatin. The regimen
           of adjuvant chemotherapy following radiation is Paclitaxel 135mg/m2 plus Cisplatin
           60mg/m2 once 3 weeks.The Grade 3/4 adverse events (CTCAE criteria ver. 4.03), the 3-year
           progression-free survival of the 2 groups, the 5-year overall survival of the 2 groups
           are compared.

        2. In Group A and Group B, both the radiation method and the regimen of concurrent
           chemotherapy are the same.The gross tumor volume (GTVnd) is the lymph node lesion and
           given a dose of 60Gy. The clinical target volume (CTV) is according to the lymph
           drainage pathway and given a dose of 45Gy. The regimen of concurrent chemotherapy is
           Cisplatin 80mg/m2 once three weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year progression-free survival (3y-PFS)</measure>
    <time_frame>3 years after the date of adjuvant chemotherapy completion</time_frame>
    <description>Percentage of patients in a treatment group who are alive without disease get worse for a 3-year period of follow-up after the date of adjuvant chemotherapy completion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3/4 adverse event</measure>
    <time_frame>Once a week during therapy, up to 5 years after the date of adjuvant chemotherapy completion</time_frame>
    <description>Incidence of patients in a treatment group who manifest a specific adverse event (such as myelosuppression) of grade 3/4. Incidence is calculated for each adverse event respectively and severity is evaluated on basis of Common Terminology Criteria for Adverse Events (CTCAE) criteria ver. 4.03.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>5-year overall survival (5y-OS)</measure>
    <time_frame>5 years after the date of adjuvant chemotherapy completion</time_frame>
    <description>Percentage of patients in a treatment group who are alive for a 5-year period of follow-up after the date of adjuvant chemotherapy completion</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">432</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Adjuvant Chemotherapy</condition>
  <condition>Radiation</condition>
  <condition>Lymph Node Metastases</condition>
  <arm_group>
    <arm_group_label>The control group (Group A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Group A, observation is given after chemoradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The experiment group (Group B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in Group B, three cycles of Paclitaxel, Cisplatin are administered after radiation with concurrent cisplatin. The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel 135mg/m2 plus Cisplatin 60mg/m2 once 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>chemoradiation</intervention_name>
    <description>radiation with concurrent ciplatin</description>
    <arm_group_label>The control group (Group A)</arm_group_label>
    <arm_group_label>The experiment group (Group B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel, Cisplatin</intervention_name>
    <description>The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel, Cisplatin once 3 weeks.</description>
    <arm_group_label>The experiment group (Group B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically diagnosed cervical cancer;

          2. pelvic or para-aortic lymph metastases, at least match one of following

               -  CT or MRI scan shows pelvic or para-aortic node with a minimal axial diameter
                  diameter ≥ 7mm in the largest plane

               -  pelvic or para-aortic lymph node shows necrosis or extra capsular spread

               -  PET/CT scan finds positive pelvic or para-aortic node lymph node

               -  biopsy confirms lymph metastase

          3. Stage IB1-IVA diseases (FIGO system ver. 2014) without treatment before;

          4. Karnofsky Performance Scores ≥ 70;

        Exclusion Criteria:

          1. Patients with distant metastasis before or during radiotherapy

          2. Severe dysfunction of heart, lung, liver, kidney or hematopoietic system

          3. Severe neurological, mental or endocrine diseases

          4. History of other malignancies

          5. Those who are considered by the researchers unsuitable to participate -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei-jun Ye, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei-jun Ye, M.D</last_name>
    <phone>86-13538799871</phone>
    <email>yewj@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junyun Li, M.D</last_name>
    <phone>86-18824712702</phone>
    <email>LIJUNY@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Affiliated Foshan Hospital</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rong Huang, M.D</last_name>
      <phone>86-13927736853</phone>
      <email>nnjbhg@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of of Guangdong Armed Police Corps</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhen-lun Li, M.D</last_name>
      <phone>86-13580516205</phone>
      <email>sfqiu@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei-jun Ye, M.D</last_name>
      <phone>86-13538799871</phone>
      <email>yewj@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Junyun Li, M.D</last_name>
      <phone>86-18824712702</phone>
      <email>LIJUNY@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The First affiliated Hospital of Guangdong Pharmaceutical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xi-cheng Wang, M.D</last_name>
      <phone>86-13902400598</phone>
      <email>13902400598@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guo-long Liu, M.D</last_name>
      <phone>86-13802527172</phone>
      <email>liugl@fimmu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jia-xin Chen</last_name>
      <phone>86-13978609888</phone>
      <email>cjx166@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guang Huang, M.D</last_name>
      <phone>86-18089777161</phone>
      <email>2842749787@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinjiang Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Ürümqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiao-wen Li, M.D</last_name>
      <phone>86-13899856295</phone>
      <email>lixiaowen1026@sohu.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Wei-jun Ye</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

